Severe uncontrolled asthma in children is a complex and heterogeneous disease and is considered a challenge for the pediatricians. Although nearly 5% of children with asthma present with a severe uncontrolled disease, these patients and their caregivers face a significant burden, including troublesome persistent symptoms, life-threatening acute attacks, medication side effects, impaired school performance, neuropsychological problems, and lower quality of life (QoL). Moreover, these patients also account for substantially higher healthcare resource use and costs than average patients with asthma. Thus, it is essential to accurately define and diagnose severe asthma in children as they potentially need close monitoring and additional treatment with advanced therapies. This review aims to update knowledge on diagnosis and management of severe uncontrolled asthma in childhood. We describe a practical approach to differentiate children with difficult-to-treat asthma from those with true severe therapy-resistant asthma. Moreover, the recent advances in the understanding of the pathogenetic mechanisms and inflammatory mediators involved in asthma have paved the way for the development of a precision medicine approach. In this context, we analyze approved personalized therapies for severe uncontrolled asthma, focusing on the pediatric indications.

Severe uncontrolled asthma in children: Practical approach on diagnosis and management

Castagnoli R.;Marseglia A.;Brambilla I.;Marseglia G. L.;Licari A.
2020-01-01

Abstract

Severe uncontrolled asthma in children is a complex and heterogeneous disease and is considered a challenge for the pediatricians. Although nearly 5% of children with asthma present with a severe uncontrolled disease, these patients and their caregivers face a significant burden, including troublesome persistent symptoms, life-threatening acute attacks, medication side effects, impaired school performance, neuropsychological problems, and lower quality of life (QoL). Moreover, these patients also account for substantially higher healthcare resource use and costs than average patients with asthma. Thus, it is essential to accurately define and diagnose severe asthma in children as they potentially need close monitoring and additional treatment with advanced therapies. This review aims to update knowledge on diagnosis and management of severe uncontrolled asthma in childhood. We describe a practical approach to differentiate children with difficult-to-treat asthma from those with true severe therapy-resistant asthma. Moreover, the recent advances in the understanding of the pathogenetic mechanisms and inflammatory mediators involved in asthma have paved the way for the development of a precision medicine approach. In this context, we analyze approved personalized therapies for severe uncontrolled asthma, focusing on the pediatric indications.
2020
Medical Research, General Topics covers a wide array of topics in medical and biomedical research, with a specific emphasis on human disease, human tissues, and all levels of research into the pathogenesis of clinically significant conditions. Specific medical fields that are characterized by the inclusion of material from several other specializations are also covered here; these include general and internal medicine, tropical medicine, pediatrics, gerontology, epidemiology, and public health. Resources dealing with specific clinical interventions are excluded and are placed in the Medical Research: Diagnosis & Treatment category. Resources that emphasize the specific disease types, or specific systems affected are also excluded and are categorized according to the pathogen or system pathophysiology.
Esperti anonimi
Inglese
Internazionale
ELETTRONICO
72
3
196
205
10
Asthma, prevention and control; Asthma, therapy; Diagnosis; Dupilumab; Mepolizumab; Omalizumab
no
5
info:eu-repo/semantics/article
262
Castagnoli, R.; Marseglia, A.; Brambilla, I.; Marseglia, G. L.; Licari, A.
1 Contributo su Rivista::1.1 Articolo in rivista
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1344462
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact